All the Drug Class Drugs
Thrombopoiesis Stimulating Protein. Romiplostim 250 mcg. VIAL(pwdr. for sol.for S.C. inj.):5 ml×250 mcg. Individ. pt. dose (mcg) = wt. (kg) × dose in mcg/kg.
Actual body wt. at initiat. of tmt. should always be used when calculat. init. dose.
In adult., future dose adjust. are based on changes in platelet counts only.
In ped. pts., future dose adjust. are based on changes in platelet counts and changes in bdy. wt. Reassessm. of body wt. is recomm. every 12 wks. If individ. pt. dose is≥23 mcg: Reconstit. lyophiliz.: The result. conc. is 500 mcg/mL. Volume to admin. (mL) = Individ. pt. dose (mcg)/500 mcg/mL (Round volume to the nearest hundredth mL). See lit.
If individ. pt. dose is<23 mcg-Dilut. is requir. to ensure accurate dosing. Reconstit. lyophilized product and then dilute the product: The result. conc. is 125 mcg/mL. Volume to administer (mL) = Individ. pt. dose (mcg)/125 mcg/mL (Round volume to the nearest hundredth mL). See lit. Dose adjust.: A subject’s actual bdy. wt. at init. of ther. should be used to calculate dose. The once wkly. dose of romiplostim should be incr. by increm. of 1 mcg/kg until the pt. achieves a platelet count ≥ 50 x 10^9/L. Platelet counts should be assessed wkly. until a stable platelet count (≥ 50 x 10^9/L for at least 4 wks. without dose adjust.) has been achieved. Platelet counts should be assessed monthl. See lit.
Adlt: Tmt. primy immune thrombocytopenia (ITP) pts. who are refract. to other tmt. (e.g. corticosteroids, immunoglobulins).
Ped: Tmt. primy immune thrombocytopenia (ITP) pts. one year of age and older who are refract. to other tmt. (e.g. corticosteroids, immunoglobulins).
C/I: Hypersens. Hypersens. to E. coli derived proteins.
